Oxlumo 94.5 mg/0.5 mL solution for injection
*Company:
Alnylam UK Ltd.Status:
No Recent UpdateLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 19 November 2024
File name
Oxlumo EU - PIL-CLN.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 19 November 2024
File name
Oxlumo EU- SmPC-CLN.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 13 June 2023
File name
Oxlumo SmPC -IE.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Updated following carcinogenicity
Updated on 13 June 2023
File name
Oxlumo SmPC -IE.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 13 June 2023
File name
Oxlumo SmPC -IE.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 19 January 2023
File name
SmPC-IE-Oxlumo.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to restricted prescription (C)
Updated on 16 December 2021
File name
2021-12-16-Oxlumo EU SmPC Mouse Study IE.pdf
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to restricted prescription (C)
Updated on 02 November 2021
File name
pil luma.pdf
Reasons for updating
- New PIL for new product
Updated on 01 November 2021
File name
spc luma.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)